Search Results

You are looking at 51 - 60 of 947 items for :

  • "NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines" x
  • Refine by Access: All x
Clear All
Full access

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Naresh Bellam, William Blum, Michael W. Boyer, Hetty E. Carraway, Peter F. Coccia, Steven E. Coutre, Jennifer Cultrera, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Haydar Frangoul, Olga Frankfurt, Salil Goorha, Michael M. Millenson, Susan O'Brien, Stephen H. Petersdorf, Arati V. Rao, Stephanie Terezakis, Geoffrey Uy, Meir Wetzler, Andrew D. Zelenetz, Maoko Naganuma, and Kristina M. Gregory

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Acute Lymphoblastic Leukemia (ALL) were developed as a result of meetings convened by a multidisciplinary panel of ALL experts, with the goal of providing recommendations on standard

Full access

William T. McGivney

The National Comprehensive Cancer Network (NCCN) and our 21 member institutions are dedicated to improving the care available to patients around the world. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) and the attendant

Full access

Jerald P. Radich

-positive (Ph+) marrow metaphases,” as they correspond to long-term outcomes such as progression-free and overall survival (OS). The treatment options recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for chronic-phase CML

Full access

Andrew D. Zelenetz and Pamela S. Becker

granulocyte colony-stimulating factor (G-CSF) filgrastim-sndz. Filgrastim-sndz is now listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors (MGFs) and is part of many drug formularies. The oncology community

Full access

Robert W. Carlson and Eric Jonasch

NCCN Evidence Blocks to Guide Decision-Making NCCN recently introduced NCCN Evidence Blocks into a number of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to assist clinicians and patients as they grapple with treatment

Full access

Waleed A. Hassen, Farrok A. Karsan, Farhat Abbas, Yasar Beduk, Ahmed El-Khodary, Marwan Ghosn, Jamal Khader, Raja Khauli, Danny M. Rabah, Ali Shamseddine, and Sandy Srinivas

Africa (MENA) region is not completely known. A prostate cancer committee was established to modify the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Prostate Cancer for adaptation and implementation in the MENA region. The objective

Full access

David S. Ettinger, Michael Kuettel, Jennifer Malin, Joan S. McClure, Mary Lou Smith, Andrew D. Zelenetz, and F. Marc Stewart

Clinical Practice Guidelines in Oncology (NCCN Guidelines) from some of the members who were in the delivery room when they were born. For example, in 1996, the NCCN Guidelines for Lung Cancer were created by a 7-member lung cancer panel and included 40

Full access

Ali Bazarbachi and Andrew D. Zelenetz

East and North Africa) region guideline committees began the process of modifying the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for several tumor types, including lymphoma. The MENA region includes Morocco, Algeria, Tunisia

Full access

Kenneth C. Anderson

Practice Guidelines in Oncology (NCCN Guidelines) for multiple myeloma regarding transplant candidates were updated to include this triplet as an initial treatment option under “other regimens.” This joins a growing list of triplets that greatly increase

Full access

Arti Hurria

. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Senior Adult Oncology include a comprehensive geriatric assessment that can be used to help predict the risk of toxicity from cancer treatment in older patients. Along with age